(PETS) PetMed Express - Ratings and Ratios
Medications, Supplements, Hygiene, Supplies
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 65.4% |
| Value at Risk 5%th | 87.3% |
| Relative Tail Risk | -18.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.04 |
| Alpha | -54.07 |
| CAGR/Max DD | -0.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.542 |
| Beta | 1.077 |
| Beta Downside | 1.236 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.37% |
| Mean DD | 66.99% |
| Median DD | 78.22% |
Description: PETS PetMed Express December 27, 2025
PetMed Express Inc. (NASDAQ:PETS) operates a U.S.-focused online pet pharmacy that sells both prescription and over-the-counter medications, health products, and ancillary pet supplies for dogs, cats, and horses. Sales are fulfilled through its website, mobile app, a call-center, and direct-mail marketing, with the company headquartered in Delray Beach, Florida, and incorporated in 1996.
Key recent metrics (FY 2023): revenue of $1.05 billion, a 7 % year-over-year increase driven primarily by higher prescription-drug volumes and a 12 % rise in average order value; gross margin improved to 38 % from 35 % in 2022 as the mix shifted toward higher-margin generics; and net loss of $45 million, reflecting continued investment in logistics and marketing. The pet-pharmacy market is expanding at roughly 9 % CAGR, propelled by the “humanization” of pets and growing veterinary prescription-drug utilization, while e-commerce penetration in pet supplies is now above 45 % of total spend.
Sector drivers that materially affect PETS include (1) overall pet-care spending, which the American Pet Products Association projects to exceed $120 billion in 2025; (2) regulatory trends around veterinary telehealth and e-prescribing, which could lower customer acquisition costs; and (3) competitive pressure from large e-retailers such as Chewy and 1-800-Pets, which intensifies price competition and necessitates differentiation through formulary breadth and fulfillment speed.
For a deeper, data-rich analysis of PETS’ valuation assumptions and scenario modeling, you may find the free tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-41.1m TTM) > 0 and > 6% of Revenue (6% = 12.5m TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA -26.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1.33% (prev 7.14%; Δ -5.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.27 (>3.0%) and CFO -27.5m > Net Income -41.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (20.9m) change vs 12m ago -0.25% (target <= -2.0% for YES) |
| Gross Margin 28.37% (prev 25.40%; Δ 2.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 164.5% (prev 177.3%; Δ -12.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -24.79 (EBITDA TTM -2.56m / Interest Expense TTM 326.0k) >= 6 (WARN >= 3) |
Altman Z'' 0.97
| (A) 0.03 = (Total Current Assets 59.5m - Total Current Liabilities 56.7m) / Total Assets 100.3m |
| (B) 0.24 = Retained Earnings (Balance) 23.9m / Total Assets 100.3m |
| (C) -0.06 = EBIT TTM -8.08m / Avg Total Assets 126.5m |
| (D) 0.42 = Book Value of Equity 23.9m / Total Liabilities 57.2m |
| Total Rating: 0.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 14.75
| 1. Piotroski 2.50pt |
| 2. FCF Yield -91.98% |
| 3. FCF Margin -15.55% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda 13.81 |
| 6. ROIC - WACC (= -21.50)% |
| 7. RoE -57.17% |
| 8. Rev. Trend -57.80% |
| 9. EPS Trend -51.75% |
What is the price of PETS shares?
Over the past week, the price has changed by +0.61%, over one month by +106.21%, over three months by +30.71% and over the past year by -30.40%.
Is PETS a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PETS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.8 | -17.2% |
| Analysts Target Price | 2.8 | -17.2% |
| ValueRay Target Price | 2.4 | -28.9% |
PETS Fundamental Data Overview January 04, 2026
P/S = 0.3557
P/B = 1.5883
P/EG = 2.58
Beta = 0.767
Revenue TTM = 208.1m USD
EBIT TTM = -8.08m USD
EBITDA TTM = -2.56m USD
Long Term Debt = 768.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 477.0k USD (from shortTermDebt, last quarter)
Debt = 768.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.3m USD (from netDebt column, last quarter)
Enterprise Value = 35.2m USD (70.5m + Debt 768.0k - CCE 36.1m)
Interest Coverage Ratio = -24.79 (Ebit TTM -8.08m / Interest Expense TTM 326.0k)
EV/FCF = -1.09x (Enterprise Value 35.2m / FCF TTM -32.4m)
FCF Yield = -91.98% (FCF TTM -32.4m / Enterprise Value 35.2m)
FCF Margin = -15.55% (FCF TTM -32.4m / Revenue TTM 208.1m)
Net Margin = -19.73% (Net Income TTM -41.1m / Revenue TTM 208.1m)
Gross Margin = 28.37% ((Revenue TTM 208.1m - Cost of Revenue TTM 149.1m) / Revenue TTM)
Gross Margin QoQ = 27.98% (prev 28.14%)
Tobins Q-Ratio = 0.35 (Enterprise Value 35.2m / Total Assets 100.3m)
Interest Expense / Debt = 42.45% (Interest Expense 326.0k / Debt 768.0k)
Taxrate = -0.11% (negative due to tax credits) (9000 / -8.51m)
NOPAT = -8.09m (EBIT -8.08m * (1 - -0.11%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.05 (Total Current Assets 59.5m / Total Current Liabilities 56.7m)
Debt / Equity = 0.02 (Debt 768.0k / totalStockholderEquity, last quarter 43.1m)
Debt / EBITDA = 13.81 (negative EBITDA) (Net Debt -35.3m / EBITDA -2.56m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -35.3m / FCF TTM -32.4m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.45% (Net Income -41.1m / Total Assets 100.3m)
RoE = -57.17% (Net Income TTM -41.1m / Total Stockholder Equity 71.8m)
RoCE = -11.13% (EBIT -8.08m / Capital Employed (Equity 71.8m + L.T.Debt 768.0k))
RoIC = -11.27% (negative operating profit) (NOPAT -8.09m / Invested Capital 71.8m)
WACC = 10.23% (E(70.5m)/V(71.3m) * Re(9.88%) + D(768.0k)/V(71.3m) * Rd(42.45%) * (1-Tc(-0.00)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
Fair Price DCF = unknown (Cash Flow -32.4m)
EPS Correlation: -51.75 | EPS CAGR: -10.63% | SUE: 0.24 | # QB: 0
Revenue Correlation: -57.80 | Revenue CAGR: -10.55% | SUE: 4.0 | # QB: 1
EPS current Year (2026-03-31): EPS=-0.22 | Chg30d=-0.100 | Revisions Net=-1 | Growth EPS=+26.7% | Growth Revenue=-12.3%
EPS next Year (2027-03-31): EPS=0.01 | Chg30d=+0.090 | Revisions Net=+1 | Growth EPS=+104.6% | Growth Revenue=+3.0%
Additional Sources for PETS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle